FranceFrance

Genome profiler launches IPO

10.07.2010

Paris – This year’s third small IPO went out on the Alternext market of Euronext Paris this year, with molecular diagnostics company IntegraGen S.A. raising EUR6.7m through the sale of 800,149 shares at a8.40, giving it a post-money valuation of EUR31.7m. Founded in 2000, IntegraGen is using its Genome Hybrid Identity Profiling approach to identify disease genes by analysing the shared genes among a small sample of family members with a given disease. The goal is to develop and distribute molecular diagnostics based on the identified markers. The company is focused on cancer and autism. In the oncology setting, IntegraGen recently signed a partnership with in vitro diagnostics specialists BioMerieux S.A. to create a molecular diagnostics laboratory within the Assistance Publique Hôpitaux de Paris. The main goal of this partnership is to validate biomarkers. With the proceeds from the IPO, IntegraGen says it plans to launch a pair of biomarker assays for hepato­cellular carcinoma and metastatic colorectal cancer by 2013. In addition, IntegraGen has identified eight SNPs associated with a doubled risk of autism.
Two other IPOs went on the Alternext in April. Autoimmune and inflammation company Neovacs S.A. raised EUR10m, while bioprocessing specialist Deinove S.A. brought in EUR12.1m.

FranceFrance

05.01.2012

Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...

FranceFrance

17.12.2011

Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...

FranceFrance

01.11.2011

Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...

FranceFrance

26.10.2011

Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...

FranceFrance

20.10.2011

Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...

FranceFrance

10.10.2011

Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...

FranceFrance

01.10.2011

Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance

09.09.2011

Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/1/article/genome-profiler-launches-ipo.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SUMMIT (UK)4.03 GBP3.87%
  • DEINOVE (F)13.32 EUR2.46%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • CELLECTIS (F)13.54 EUR112.6%
  • ADDEX (CH)4.54 CHF108.3%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-42.9%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events